Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

v3.22.2.2
Subsequent Events
3 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
Subsequent events

9 Subsequent events

 

REM-001 program pause

Subsequent to September 30, 2022, the Company made the decision to pause the REM-001 program. Costs relating to the decision to pause the program will be recognized as incurred and will be expensed as there is no future benefit to the REM-001 clinical development expenses created by the pause decision. No costs relating to the pause decision have been recognized as of September 30, 2022.

Stock Options

Subsequent to September 30, 2022, 267 stock options at an exercise price of $1.70 per share expired.

 

The Company has evaluated its subsequent events from September 30, 2022, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted above.